Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that it will release the latest preclinical data of ATG-201 (CD19 x CD3 TCE) in Poster Presentations at the 2025 American College of Rheumatology (ACR) Annual Meeting, taking place from October 24th to October 29th in Chicago, IL, the United States.

AnTenGager^TM is Antengene's proprietary TCE 2.0 platform featuring "2+1" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. ATG-201 is a novel "2+1" CD19-targeted T-cell engager developed on the AnTenGager^TM TCE platform for the treatment of autoimmune diseases. ATG-201 is poised to enter clinical development in Q4 2025.

Details of the Poster Presentations:
ATG-201 (CD19 x CD3 TCE)
Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Abstract Number: 0001
Session: (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I
Date: Sunday, October 26
Time: 10:30 AM - 12:30 PM (Central Time)
           00:30 AM - 02:30 AM, October 27 (Beijing Time)

Forward-looking Statements:
For details on forward-looking statements, please refer to our full Interim Results press release on the Company's website: https://www.antengene.com/newsinfo/442

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: [email protected]  
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: [email protected] 
Mobile: +86 13062747000

Logo - https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg